A prospective cohort study assessing the efficacy and safety of Tarceva® in 2nd line in patients with locally advanced or metastatic squamous Non-Small Cell Lung Cancer (NSCLC) – PEPiTA study FRESH-PEF74127-en Camille BACHOT A prospective cohort study assessing the efficacy and safety of Tarceva® in 2nd line in patients with locally advanced or metastatic squamous Non-Small Cell Lung Cancer (NSCLC) – PEPiTA study PEPITA FRESH-PEF74127-en 74127 FRESH-PEF74127 NCT01659970 F. HOFFMANN-LA ROCHE AG Epidemiology France Portal (PEF) null ;Medical data center ERLOTINIB Oncology Carcinoma in situ of middle ear or respiratory system Healthcare system determinants: Use of care Healthcare system determinants Primary objective: To describe Progression Free Survival (PFS) in patients with stage IIIB or IV squamous NSCLC initiating treatment with Tarceva® after failure of first-line platinum-based chemotherapy. Secondary objectives: - To describe characteristics of patients treated with Tarceva®; - To describe Tarceva® treatment modalities in patients with squamous NSCLC after failure of first-line platinum-based chemotherapy; - To evaluate Overall Survival (OS); - To describe the evolution of QoL; - To describe the safety profile of Tarceva®. null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Inclusion criteria: 1. Adult patients (age >= 18 years); 2. Histologically and/or cytologically confirmed advanced (stage IIIB) or metastatic (stage IV) NSCLC with predominant squamous component (basaloid carcinomas allowed), after failure of first-line platinum-based chemotherapy; 3. For whom the treating physician decided to initiate treatment with Tarceva®; 4. Having received oral and written information about the study and having raised no objections to the collection and analysis of his/her personal data. 1. Mixed non-small cell and small cell lung carcinoma or mixed squamous cell carcinoma with a predominant adenocarcinoma component; 2. Concomitant participation in a clinical trial evaluating an antineoplastic treatment. Clinical data Biological data CDISC GCP/GVP Health event/morbidity Health event/mortality Health care consumption and services Quality of life/health perception Other Through organizations (health services or institutions schools businesses etc.) < 500 individuals Converting or copying information into a structured record Observational Study Observational Study Cohort study 152 Unknown Restricted access Access on specific project only